These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 8000101

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, Parkinson Study Group.
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP, Kempster PA, Stibe CM, Eatough VM, Nathanson M, Lees AJ, Stern GM.
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH, Myllylä V.
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T, Yahr MD.
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA.
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
    Mizuno Y, Kondo T, Kuno S, Nomoto M, Yanagisawa N.
    Clin Neuropharmacol; 2010 Dec; 33(1):1-4. PubMed ID: 19935410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.